Bredesen Protocol
Dr. Dale Bredesen, of the Buck Institute for Research on Aging and UCLA's Mary S. Easton Center for Alzheimer's Disease Research, is a scientist who has been studying Alzheimer's disease for 30 years and has come up with a way to reverse it in its early stages. His initial protocol involved 25 different interventions which individually don't make a big difference, but together can provide powerful synergistic benefits.
Each intervention is tweaked over time by using blood tests, body measurements, imaging and similar guides to measure its effect. In his initial paper, nine out of ten patients reversed their memory problems and returned to their former healthy level of functioning. The one who didn't show improvement was past the early stages of Alzheimer's.
Dr. Bredesen has since expanded the protocol and number of patients seen. He is in the process of making it available to the wider public with the help of doctors certified in the protocol through MPI Cognition.
Dr. Bredesen was previously affiliated with Muses Labs.
This page sets out to explain the 25 treatments in simple enough language that untrained people suffering from Alzheimer's (or their caregivers) can begin to implement the easier ones while working with their doctors or other labs to begin the others.
Here are the interventions used in The Bredesen Protocol™ to reverse mild Alzheimer's:
2. Enhance autophagy, ketogenesis
5. Exercise
7. Homocysteine less than 6 (earlier version of the protocol was < 7)
9. CRP less than 1.0; A/G greater than 1.8 (earlier version of the protocol was > 1.5)
10. Fasting insulin less than 5; HgbA1c less than 5.6 (earlier version of the protocol was Fasting insulin <7; HgbA1c <5.5)
11. Hormone balance
12. GI health
13. Reduction of Aß
15. 25OH-D3 = 50-80ng/ml (earlier version of the protocol was 50-100)
16. Increase NGF
17. Provide synaptic structural components
20. Ensure nocturnal oxygenation
21. Optimize mitochondrial function
22. Increase focus
24. Exclude heavy metal toxicity
25. MCT effects
=== For further reading and information on Dr Bredesen's research ===
Book
Dr Bredesen's book, The End of Alzheimer's: The First Program to Prevent and Reverse Cognitive Decline, published August 22, 2017. Amazon link to Dr Bredesen's book
Videos and interviews
- Videos are available on the MPI Cognition website www.mpicognition.com
- There is a long, but very good STEM Talk interview with Dr Bredesen available on YouTube, Published on Jun 1, 2016 Episode 12 Dale Bredesen discusses the metabolic factors underlying Alzheimer’s Disease
- Presentation given by Dr Bredesen at the Integrative Healthcare Symposium (IHS) Pre-Conference - Feb. 24, 2016 in Midtown, New York City IHS 2016 -Cognitive Health: Dawn of the Era of Treatable Alzheimer’s Disease
- 36 Holes in the Roof, comes with a very nice illustrative video, published Mar 25, 2015 36 ‘Holes in the Roof’ The Dawn of the Era of Treatable and Preventable Alzheimer’s Disease
- Dr Gundry's interview with Dr Bredesen, Published on Aug 21, 2017 Dr. Steven Gundry interviews Dr Dale Bredesen about "The End of Alzheimer's"
- Dr Mercola's interview with Dr Bredesen, with a fair discussion of ApoE4, Published on Aug 25, 2017, Dr. Mercola Interviews Dr. Bredesen About ReCODE Protocol
- Dr Perlmutter, author of "The Grain Brain" interviewed Dr Bredesen on Dec 4, 2017. Dr Bredesen also took questions from the audience. Dr Perlmutter and Dr Bredesen
Dr Bredesen's Papers
- The first version of Dr Bredesen’s protocol (which is similar to the above) can be found in his paper: Reversal of cognitive decline: A novel therapeutic program, published September 2014, https://www.ncbi.nlm.nih.gov/pubmed/25324467
Subsequent papers of Dr Bredesen do not address his protocol, but further examine his findings, they are:
- Metabolic profiling distinguishes three subtypes of Alzheimer's disease, published in August 2015, https://www.ncbi.nlm.nih.gov/pubmed/26343025
- Direct Transcriptional Effects of Apolipoprotein E published January 2016, Dr Bredesen is co-author. https://www.ncbi.nlm.nih.gov/pubmed/26791201
- Inhalational Alzheimer’s Disease: An unrecognized – and treatable epidemic, published February 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4789584/
- Transcriptional Effects of ApoE4: Relevance to Alzheimer's Disease, published September 2017. https://www.ncbi.nlm.nih.gov/pubmed/28879423